Sandeep Laumas - 14 May 2026 Form 4/A - Amendment Insider Report for Unicycive Therapeutics, Inc. (UNCY)

Reporting relationship: Director
Issuer ticker: UNCY
Reported as of: 14 May 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 28 Jul 2026, 16:15:15 UTC
Original report date: 18 May 2026
Prior SEC filing: 12 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Sandeep Laumas

Key filing fact

Sandeep Laumas filed Form 4/A - Amendment for Unicycive Therapeutics, Inc. (UNCY) on 28 Jul 2026.

Key facts

This page summarizes Sandeep Laumas's Form 4/A - Amendment filing for Unicycive Therapeutics, Inc. (UNCY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Jul 2026, 16:15.

Change

Previous filing in this sequence was filed on 12 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001721664 Primary reporting owner

Laumas Sandeep

Relationship: Director
Address: C/O UNICYCIVE THERAPEUTICS, INC., 1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Signature: /s/ Sandeep Laumas
Signature date: 28 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UNCY transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +47,941
Change %
Price: $0.000000^*
Shares after: 47,941
Date: 14 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 47,941
Exercise price: $0.000000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.